1.52

2.70% 0.04

Pre-market: 1.56 0.04 +2.63%

Biomea Fusion Inc (BMEA)

Overview News Price History Option Chain Financials Why BMEA Down? Discussions Forecast

Biomea Fusion Inc stock is traded at $1.52, with a volume of 1.12M. It is up +2.70% in the last 24 hours and down -1.30% over the past month. Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Previous Close:

$1.48

Open:

$1.52

24h Volume:

1.12M

Relative Volume:

0.79

Market Cap:

$109.90M

Revenue:

Net Income/Loss:

$-61.80M

P/E Ratio:

-1.0002

EPS:

-1.5197

Net Cash Flow:

$-70.37M

1W Performance:

-0.65%

1M Performance:

-1.30%

6M Performance:

+13.43%

1Y Performance:

-24.00%

1-Day Range:

$1.46

$1.56

1-Week Range:

$1.28

$1.56

52-Week Range:

$0.8719

$3.08

Biomea Fusion Inc Stock (BMEA) Company Profile

Name

Biomea Fusion Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(650) 980-9099

Address

1599 INDUSTRIAL ROAD, SAN CARLOS

Employee

Twitter

Next Earnings Date

2026-05-04

Latest SEC Filings

BMEA's Discussions on Twitter

Compare BMEA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMEA Biomea Fusion Inc	1.52	109.90M	0	-61.80M	-70.37M	-1.5197
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-26	Initiated	Rodman & Renshaw	Buy
Aug-28-25	Initiated	Jefferies	Buy
Jun-03-25	Resumed	Piper Sandler	Overweight
Oct-09-24	Initiated	Edward Jones	Buy
Sep-27-24	Upgrade	Rodman & Renshaw	Neutral → Buy
Sep-27-24	Upgrade	Truist	Hold → Buy
Aug-29-24	Initiated	CapitalOne	Overweight
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-24	Initiated	Truist	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight
Mar-29-23	Reiterated	Oppenheimer	Outperform
Mar-28-23	Reiterated	H.C. Wainwright	Buy
Feb-24-23	Initiated	Citigroup	Buy
Jun-02-22	Resumed	H.C. Wainwright	Buy
Jan-12-22	Initiated	H.C. Wainwright	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
May-11-21	Initiated	JP Morgan	Overweight
May-11-21	Initiated	Jefferies	Buy
May-11-21	Initiated	Piper Sandler	Overweight

View All

Biomea Fusion Inc Stock (BMEA) Latest News

May 05, 2026

Biomea Fusion to present new icovamenib data at American Diabetes Association event - Traders Union

May 05, 2026

Biomea Fusion Announces Late-Breaking Poster Presentations on Icovamenib at ADA 86th Scientific Sessions - Quiver Quantitative

May 05, 2026

Three diabetes studies put Biomea's icovamenib in ADA late-breakers - Stock Titan

May 05, 2026

Biomea Fusion Announces Poster Presentations of Icovamenib - GlobeNewswire

May 05, 2026

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions - GlobeNewswire Inc.

May 05, 2026

Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026 - Yahoo Finance

May 05, 2026

Citizens initiates Biomea Fusion stock coverage citing diabetes treatment potential - Investing.com

May 05, 2026

May 01, 2026

Biomea Fusion Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView

May 01, 2026

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

May 01, 2026

Apr 29, 2026

BMEA Forecast, Price Target & Analyst Ratings | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill

Apr 29, 2026

Apr 28, 2026

Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib - MarketBeat

Apr 28, 2026